Stewart D. Clark

Stewart D. Clark

Auto-generated profile, based on publicly available information

Stewart D. Clark

Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, NY, USA

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in eneuro
Verified
Journal Article
Open access
PDF file
DMDuncan A. A. MacLaren
Duncan A. A. MacLaren
RBRichard W. Browne
Richard W. Browne
JSJessica K. Shaw
Jessica K. Shaw
SRSandhya Krishnan Radhakrishnan
Sandhya Krishnan Radhakrishnan
PKPrachi Khare
Prachi Khare
SCStewart D. Clark
Stewart D. Clark
Clozapine N-oxide (CNO) is a ligand for a powerful chemogenetic system that can selectively inhibit or activate neurons; the so-called Designer Receptors Exclusively Activated by Designer Drugs (DREADD) system. This system consists of synthetic G-protein-coupled receptors, which are not believed to be activated by any endogenous ligand, but are activated by the otherwise inert CNO. However, it has previously been shown that the administration of CNO in humans and rats leads to detectable levels of the bioactive compounds clozapine andN-desmethylclozapine (N-Des). As a follow-up, experiments were conducted to investigate the effects of CNO in male Long–Evans rats. It was found that 1 mg/kg CNO reduced the acoustic startle reflex but had no effect on prepulse inhibition (PPI; a measure of sensorimotor gating). CNO (2 and 5 mg/kg) had no effect on the disruption to PPI induced by the NMDA antagonist phencyclidine or the muscarinic antagonist scopolamine. In locomotor studies, CNO alone (at 1, 2, and 5 mg/kg) had no effect on spontaneous locomotion, but 5 mg/kg CNO pretreatment significantly attenuatedd-amphetamine-induced hyperlocomotion. In line with the behavioral results, fast-scan cyclic voltammetry found that 5 mg/kg CNO significantly attenuated thed-amphetamine-induced increase in evoked dopamine. However, the effects seen after CNO administration cannot be definitively ascribed to CNO because biologically relevant levels of clozapine andN-Des were found in plasma after CNO injection. Our results show that CNO has multiple dose-dependent effectsin vivoand is converted to clozapine andN-Des emphasizing the need for a CNO-only DREADD-free control group when designing DREADD-based experiments.

4 July 2014 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
DMDuncan A. A. MacLaren
Duncan A. A. MacLaren
JSJoseph A. Santini
Joseph A. Santini
ARAshley L. Russell
Ashley L. Russell
TMTamara Markovic
Tamara Markovic
SCStewart D. Clark
Stewart D. Clark

11 September 2014 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
DMDuncan A. A. MacLaren
Duncan A. A. MacLaren
TMTamara Markovic
Tamara Markovic
SCStewart D. Clark
Stewart D. Clark

8 November 2005 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
HNHans‐Peter Nothacker
Hans‐Peter Nothacker
SCStewart Clark
Stewart Clark

11 January 2021 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
NCNicole E. Chambers
Nicole E. Chambers
MCMichael Coyle
Michael Coyle
JSJordan Sergio
Jordan Sergio
KLKathryn Lanza
Kathryn Lanza
CSCarolyn Saito
Carolyn Saito
CBChristopher Bishop
Christopher Bishop

2 November 2021 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
GKGabriella King
Gabriella King
KVKaliana M. Veros
Kaliana M. Veros
DMDuncan Archibald Allan MacLaren
Duncan Archibald Allan MacLaren
MLMartin Peter Konrad Leigh
Martin Peter Konrad Leigh
JSJoseph A. Spernyak
Joseph A. Spernyak
SCStewart D. Clark
Stewart D. Clark